Adrenergic Pharmacology

Correct Answer

D — Non-selective beta-1 and beta-2 antagonist classified as a first-generation beta-blocker

Rationale

Propranolol is the prototype first-generation beta-blocker, blocking both beta-1 and beta-2 receptors with equal affinity and no receptor subtype preference. Its non-selective profile means beta-2 blockade in airway smooth muscle can cause bronchoconstriction, and beta-2 blockade in skeletal muscle vasculature removes vasodilatory tone. These effects make propranolol contraindicated in asthma and problematic in severe peripheral arterial disease. While propranolol does inhibit peripheral thyroxine to triiodothyronine conversion, this property is not part of its classification — it is a pharmacological action shared only by propranolol among beta-blockers. Metoprolol, atenolol, and bisoprolol are the selective beta-1 agents. Carvedilol and labetalol are the third-generation alpha-1 plus beta antagonists.

Correct Answer

B — Cardioselective beta-1 antagonist classified as a second-generation beta-blocker

Rationale

Metoprolol is a second-generation beta-blocker with preferential selectivity for beta-1 receptors over beta-2 receptors at standard therapeutic doses. This cardioselectivity means it produces less bronchoconstriction and peripheral vasoconstriction than first-generation non-selective agents, though the selectivity is relative and dose-dependent — at higher doses beta-2 blockade becomes clinically relevant. The extended-release formulation (metoprolol succinate) is one of only three beta-blockers with proven mortality benefit in heart failure with reduced ejection fraction. Propranolol is the non-selective first-generation agent with membrane-stabilizing activity. Carvedilol and labetalol are the third-generation alpha-1 plus beta agents. Pindolol and acebutolol are the agents with intrinsic sympathomimetic activity.

Correct Answer

A — Carvedilol

Rationale

Carvedilol is classified as a third-generation vasodilatory beta-blocker that blocks alpha-1, beta-1, and beta-2 adrenergic receptors. The alpha-1 blockade produces peripheral vasodilation in addition to the cardiac effects of beta blockade. First-generation beta-blockers (propranolol, nadolol) are non-selective without alpha blockade. Second-generation agents (metoprolol, atenolol, bisoprolol) are cardioselective beta-1 antagonists without alpha blockade.

Correct Answer

C — Labetalol

Rationale

Labetalol blocks both alpha-1 and non-selective beta (beta-1 and beta-2) adrenergic receptors. This combined receptor blockade reduces blood pressure through both reduced cardiac output (beta-1 blockade) and reduced peripheral vascular resistance (alpha-1 blockade), without the reflex tachycardia seen with pure vasodilators. Metoprolol, bisoprolol, and atenolol are all cardioselective beta-1 antagonists without alpha-blocking properties.

Correct Answer

D — Bisoprolol

Rationale

Bisoprolol is cardioselective (beta-1 selective), renally eliminated, and hydrophilic, giving it minimal central nervous system penetration compared to lipophilic agents. These properties reduce the risk of central nervous system adverse effects such as vivid dreams and depression. Propranolol is non-selective, hepatically metabolized, and highly lipophilic with significant central nervous system penetration. Carvedilol blocks alpha-1 and both beta subtypes. Metoprolol is cardioselective but more lipophilic than bisoprolol with greater central nervous system penetration.

Correct Answer

B — Atenolol

Rationale

Atenolol is cardioselective (beta-1 selective) and hydrophilic, resulting in predominantly renal elimination and minimal central nervous system penetration. Its hydrophilicity means it does not readily cross the blood-brain barrier, producing fewer central nervous system adverse effects than lipophilic agents such as propranolol or metoprolol. Propranolol is non-selective and highly lipophilic. Carvedilol blocks alpha-1 and both beta subtypes and is hepatically metabolized. Labetalol blocks alpha-1 and both beta subtypes.

Correct Answer

A — Only carvedilol, bisoprolol, and extended-release metoprolol succinate have demonstrated mortality benefit in large randomized trials and are guideline-endorsed; other beta-blockers should not be substituted

Rationale

The mortality benefit of beta-blockers in heart failure with reduced ejection fraction is agent-specific, not a class effect. Three agents have proven benefit from large randomized controlled trials: carvedilol in the US Carvedilol Heart Failure Trials and COPERNICUS trial, bisoprolol in the CIBIS-II trial, and extended-release metoprolol succinate in the MERIT Heart Failure trial. Other beta-blocker agents — including short-acting metoprolol tartrate, atenolol, propranolol, and nadolol — have not demonstrated equivalent benefit and should not be substituted when one of the three proven agents is unavailable or not tolerated. The benefit is not explained by simple beta-1 blockade, non-selective blockade, or intrinsic sympathomimetic activity properties — agents with these features have not reproduced the same outcomes in heart failure trials.

Correct Answer

C — Propranolol inhibits peripheral type 1 deiodinase, reducing conversion of thyroxine to the more biologically active triiodothyronine

Rationale

Thyroid storm involves both excess thyroid hormone levels and amplified catecholamine sensitivity. Propranolol addresses two distinct pharmacological problems. First, like all beta-blockers, it counteracts the adrenergically mediated symptoms (tachycardia, tremor, anxiety, hypertension) produced by thyroid hormone-induced beta-receptor upregulation. Second — uniquely among beta-blockers — propranolol inhibits peripheral type 1 deiodinase, the enzyme responsible for converting thyroxine to the biologically more active triiodothyronine in peripheral tissues. Reducing this conversion lowers the effective thyroid hormone activity even before thyroid hormone synthesis and release can be controlled by other agents (propylthiouracil, methimazole, iodine). Cardioselective agents such as metoprolol lack this deiodinase inhibition, making propranolol the preferred agent when both adrenergic and hormonal control are needed. Propranolol does not inhibit thyroid peroxidase, stabilize follicular cell membranes through membrane-stabilizing activity, or act selectively on upregulated beta-2 receptors.

Correct Answer

D — Chronic beta-blockade upregulates beta receptors; abrupt discontinuation exposes upregulated receptors to catecholamines, causing rebound tachycardia and increased myocardial oxygen demand that can precipitate ischemia

Rationale

Chronic beta-blocker therapy suppresses beta-receptor signaling, triggering a compensatory increase in receptor density (upregulation) in the myocardium and other tissues. When the drug is abruptly discontinued, normal circulating catecholamine levels encounter a larger-than-usual population of hypersensitive beta receptors, producing exaggerated chronotropic and inotropic responses — rebound tachycardia, hypertension, and increased myocardial oxygen demand. In patients with coronary artery disease, this increased oxygen demand against a background of fixed coronary stenosis can precipitate unstable angina or myocardial infarction. This is why beta-blockers must always be tapered gradually over one to two weeks rather than stopped abruptly, and explains the clinical rule of restarting as soon as feasible if discontinuation was unavoidable. Abrupt discontinuation does not cause coronary vasospasm, activate renin primarily, or destabilize coronary plaques through inflammatory mechanisms.

Correct Answer

B — Cardioselectivity is relative and dose-dependent; at therapeutic doses, even selective agents produce enough beta-2 blockade in hyperreactive airways to precipitate life-threatening bronchospasm

Rationale

Beta-1 selectivity refers to preferential, not exclusive, binding to beta-1 receptors. At therapeutic antihypertensive doses, cardioselective agents such as bisoprolol, metoprolol, and atenolol still occupy a fraction of beta-2 receptors — a fraction that is small in normal airways but clinically meaningful in the hyperreactive airways of an asthmatic patient. In asthma, baseline bronchomotor tone depends heavily on beta-2-mediated bronchodilation; even partial beta-2 blockade can tip the balance toward bronchoconstriction. Additionally, as doses are titrated upward for adequate blood pressure control, the selectivity ratio narrows further. Asthma is an absolute contraindication to all beta-blockers. Cardioselective agents do not block muscarinic receptors, increase leukotriene synthesis, or compete with albuterol for beta-2 receptors (albuterol is a beta-2 agonist, not a beta-1 antagonist).

Correct Answer

A — Atenolol is hydrophilic and does not penetrate the blood-brain barrier well, producing substantially less central nervous system activity than lipophilic propranolol

Rationale

The central nervous system adverse effects of beta-blockers — vivid dreams, nightmares, insomnia, fatigue, and depression — are directly related to the ability of the drug to penetrate the blood-brain barrier, which in turn is determined by lipophilicity. Propranolol is highly lipophilic and crosses the blood-brain barrier readily, achieving brain concentrations that produce meaningful central adrenergic receptor blockade and central nervous system effects. Atenolol is hydrophilic and crosses the blood-brain barrier poorly, producing minimal central nervous system drug concentrations and substantially fewer central nervous system adverse effects. Switching from a lipophilic to a hydrophilic agent is a practical clinical strategy when central nervous system adverse effects are limiting therapy. Atenolol has no intrinsic sympathomimetic activity, has a longer half-life than propranolol (not shorter), and does not involve serotonin signaling in its mechanism.

Correct Answer

C — Combined alpha-1 and beta blockade lowers maternal blood pressure through both reduced cardiac output and reduced peripheral vascular resistance, without the reflex tachycardia or uteroplacental compromise associated with pure vasodilators

Rationale

Labetalol's dual mechanism — alpha-1 receptor blockade reducing peripheral vascular resistance plus non-selective beta-blockade reducing cardiac output — produces effective blood pressure lowering without triggering reflex tachycardia. Pure vasodilators such as hydralazine reduce blood pressure through vasodilation alone, which activates baroreceptors and increases maternal heart rate; this reflex tachycardia increases myocardial oxygen demand and can compromise uteroplacental blood flow. Labetalol's beta component blunts this reflex, and the combination produces more hemodynamically stable blood pressure control in the preeclamptic or hypertensive pregnant patient. Labetalol does cross the placenta and can cause fetal bradycardia, though less than some agents; it does not relax uterine smooth muscle or activate placental nitric oxide synthase as primary mechanisms.

Correct Answer

D — Agents with intrinsic sympathomimetic activity have not demonstrated the same mortality benefit as pure antagonists in post-myocardial infarction and heart failure with reduced ejection fraction populations in clinical trials

Rationale

Intrinsic sympathomimetic activity means the agent acts as a partial agonist at the beta receptor — it occupies and partially activates the receptor while blocking full agonists from binding. This property produces less resting bradycardia than pure antagonists because some basal receptor activation is maintained, which may be advantageous in patients with a tendency toward bradycardia. However, in post-myocardial infarction and heart failure with reduced ejection fraction populations, where beta-blockers reduce mortality through reversal of chronic sympathetic overactivation and allowance of receptor resensitization, partial agonism at the receptor appears to attenuate the benefit. Clinical trials have not demonstrated the same mortality reduction with intrinsic sympathomimetic activity agents as with pure antagonists such as carvedilol, bisoprolol, and metoprolol succinate in these high-risk cardiac populations. The concern is clinical outcome data, not pharmacokinetic or lipophilicity characteristics.

Correct Answer

B — Chronic sympathetic overactivation in heart failure causes beta-receptor downregulation and myocyte apoptosis; beta-blockade interrupts this cycle, allowing receptor resensitization, reverse remodeling, and improved ejection fraction over months

Rationale

Heart failure with reduced ejection fraction is characterized by sustained activation of the sympathetic nervous system as a compensatory response to low cardiac output. Over time, chronic catecholamine exposure becomes maladaptive: beta-1 receptors in the myocardium are downregulated, myocytes undergo apoptosis, and the ventricle undergoes pathological hypertrophy and dilation. Beta-blockers interrupt this cycle by reducing catecholamine stimulation of the myocardium. With chronic beta-blockade, downregulated beta-1 receptors gradually resensitize, myocyte apoptosis is reduced, and the left ventricle undergoes reverse remodeling — the chamber size decreases and ejection fraction improves over weeks to months. The acute negative inotropic effect is transient; the benefit from interrupting maladaptive remodeling accumulates over time. Beta-blockers for heart failure work through neurohormonal modulation rather than through direct fibroblast stimulation, alpha-1 blockade (only carvedilol adds this), or purely antiarrhythmic mechanisms.

Correct Answer

C — The acute negative inotropic effect of beta-blockade can further reduce an already compromised cardiac output in a decompensated, volume-overloaded patient, worsening hemodynamic instability

Rationale

Beta-blockers improve long-term outcomes in heart failure with reduced ejection fraction through neurohormonal modulation, but this benefit requires time to develop. Acutely, beta-blockade reduces heart rate and contractility — the very hemodynamic parameters that a decompensated heart failure patient needs to maintain adequate forward output. In a volume-overloaded patient with low cardiac output who may already be dependent on elevated sympathetic tone to sustain perfusion, initiating a beta-blocker can precipitate acute hemodynamic deterioration, cardiogenic shock, or the need for inotropic support. Beta-blockers for heart failure must be initiated only when the patient is clinically stable and euvolemic, then started at the lowest available dose and titrated slowly over weeks. Patients who are already established on beta-blockers and develop acute decompensation should generally continue their beta-blocker rather than having it abruptly discontinued unless hemodynamic instability is severe. Carvedilol is guideline-endorsed for heart failure and its alpha-1 blockade provides afterload reduction that is beneficial rather than harmful.

Correct Answer

A — Propranolol uniquely inhibits peripheral type 1 deiodinase, reducing conversion of thyroxine to triiodothyronine and lowering biologically active thyroid hormone levels in addition to controlling adrenergic symptoms

Rationale

In thyroid storm, excess thyroid hormone upregulates beta-receptor expression and amplifies catecholamine sensitivity, producing the sympathomimetic syndrome. All beta-blockers address the adrenergic component by blocking these upregulated receptors. However, propranolol has an additional mechanism unique among beta-blockers: it inhibits peripheral type 1 deiodinase, the enzyme that converts thyroxine (the less active form secreted by the thyroid) to triiodothyronine (the biologically more active form responsible for most thyroid hormone effects in peripheral tissues). By reducing this conversion, propranolol lowers the effective thyroid hormone burden at the cellular level, providing benefit beyond simple symptom control. This second mechanism is the specific reason propranolol is preferred over metoprolol, atenolol, or bisoprolol in thyroid storm, regardless of any considerations about non-selectivity or duration of action. Propranolol does not inhibit thyroid-stimulating hormone secretion from the pituitary.

Correct Answer

D — Atenolol is hydrophilic and crosses the blood-brain barrier poorly, producing minimal central nervous system drug concentrations and substantially fewer central adrenergic adverse effects than lipophilic metoprolol

Rationale

The central nervous system adverse effects of beta-blockers — vivid dreams, nightmares, insomnia, fatigue, and depression — are attributable to brain penetration and central adrenergic receptor blockade, which is a function of lipophilicity. Metoprolol is lipophilic and crosses the blood-brain barrier readily, achieving concentrations in the brain that block central beta-receptors involved in sleep architecture regulation. Atenolol is hydrophilic and penetrates the blood-brain barrier minimally, producing negligible brain drug concentrations. The switch from metoprolol to atenolol maintains peripheral antihypertensive and cardiac beta-1 blockade while dramatically reducing central nervous system exposure, explaining the anticipated improvement in sleep disturbance and related symptoms. Atenolol has no intrinsic sympathomimetic activity, has a longer half-life than metoprolol (not shorter), and does not selectively block cerebral cortex beta-2 receptors.

Correct Answer

B — Upregulated beta-receptors from chronic blockade become hypersensitive to normal catecholamine levels after drug discontinuation, producing rebound tachycardia and increased myocardial oxygen demand that precipitate ischemia

Rationale

Chronic beta-blocker therapy suppresses beta-adrenergic signaling, causing compensatory upregulation of beta-receptor density in the myocardium and other tissues. When the drug is abruptly discontinued, the upregulated receptor population is suddenly exposed to normal circulating catecholamine levels. Because there are more receptors available and each may be hypersensitive from prolonged suppression, catecholamine signaling is amplified — producing rebound tachycardia, hypertension, and markedly increased myocardial oxygen demand. In a patient with coronary artery disease and fixed coronary stenoses, this demand-supply mismatch precipitates ischemia. The risk of acute coronary events including unstable angina and myocardial infarction is well established in the days following abrupt beta-blocker discontinuation, particularly in patients with known coronary artery disease. Beta-blocker withdrawal does not cause platelet activation, coronary vasospasm through beta-2 pathways, or clinically meaningful activation of the renin-angiotensin-aldosterone system at a level that would produce acute ischemia.